Focus: Coronavirus Channel Featured Story TOP

• share
• favorite_border

New research has revealed how light can be used to destroy infectious coronavirus particles that contaminate surfaces.

• share
• favorite_border

Researchers at Johns Hopkins Medicine say their new studies suggest that the first pandemic-accelerating mutation in the SARS-CoV-2 virus, which causes COVID-19, evolved as a way to correct vulnerabilities caused by the mutation that started the SARS-CoV-2 pandemic.

• share
• favorite_border

The Pfizer-BioNTech COVID-19 vaccine limits transmission, hospitalization, and death from COVID-19 even among patients infected by variants of the virus, but the effectiveness of antibodies it generates diminishes as patients get older, according to a study by UT Southwestern researchers.

• share
• favorite_border

A new study conducted in England shows that the risk of death due to COVID-19 remains very low for children and young people, and most deaths occur in those with underlying health conditions. Marta Bertran of the UK Health Security Agency, London, and colleagues present these findings on November 8th in the open access journal PLOS Medicine.

• share
• favorite_border

Researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease Modeling identified how a specific protein in SARS-CoV-2, the virus responsible for COVID-19, damages heart tissue. They then used a drug to reverse the toxic effects of that protein on the heart.

• share
• favorite_border

UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.

• share
• favorite_border

A vaccine that could protect against new variants of SARS-CoV-2 and also potentially protect against other coronaviruses is one step closer to reality thanks to College of Medicine researchers.

• share
• favorite_border

University of Maryland School of Medicine researchers have identified how multiple genes of SARS-CoV-2 affect disease severity, which could lead to new ways in how we develop future vaccines or develop newer treatments. The genes control the immune system of the host, contributing to how fiercely the body responds to a COVID-19 infection.

• share
• favorite_border

Being vaccinated with at least two doses of Pfizer vaccines dramatically reduces most of the long-term symptoms individuals reported months after contracting COVID-19, a new study shows.

• share
• favorite_border

Newly compiled data evaluated by researchers in the Department of Neurology and the Smidt Heart Institute at Cedars-Sinai shows that COVID-19 vaccines do not raise stroke risk--but that severe COVID-19 infection does. Physician-scientists hope this growing body of evidence, highlighted today in an editorial in the peer-reviewed journal Neurology, will ease the minds of individuals still hesitant to be vaccinated.

• share
• favorite_border

Patients with prior COVID may be twice as likely to have unhealthy endothelial cells that line the inside of the heart and blood vessels, according to newly published research from Houston Methodist. This finding offers a new clue in understanding COVID-19’s impact on cardiovascular health.

• share
• favorite_border

In a pair of related studies, UC San Diego researchers show that the origin of the COVID-19 pandemic was at a Chinese market and resulted from at least two instances of the SARS-CoV-2 virus jumping from live animal hosts to humans working or shopping there.

• share
• favorite_border

An international team of 18 researchers have determined that the earliest cases of COVID-19 in humans arose at a wholesale fish market in Wuhan China in December, 2019. They linked these cases to bats, foxes and other live mammals infected with the virus sold in the market either for consumption as meat or for their fur.

• share
• favorite_border

Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.

• share
• favorite_border

In a new study sponsored by the Centers for Disease Control and Prevention and published in the New England Journal of Medicine, researchers provide additional evidence that COVID-19 vaccination during pregnancy helps protect babies younger than 6 months from being hospitalized due to COVID-19. The risk of COVID-19 hospitalization among babies was reduced by about 80 percent during the Delta wave (July 1–December 18, 2021) and 40 percent during the Omicron wave (December 19–March 8, 2022).

• share
• favorite_border

Participants in the study who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a flu shot or COVID-19 jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization.

• share
• favorite_border

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.

• share
• favorite_border

A new international study offers a clearer picture of the impact of COVID-19 infection and the risk of severe outcomes on young people around the world.

• share
• favorite_border

First on the list: Get vaccinated and get a booster shot if you qualify.